Novavax's COVID-19 Vaccine For Adults Gets CDC Advisory Committee Recommendation

  • The U.S. Centers for Disease Control and Prevention's (CDC) advisory committee recommended using Novavax Inc's NVAX COVID-19 vaccine as a two-dose primary series for individuals aged 18 and above.
  • The committee will submit its recommendation to the Director of the CDC for review and endorsement.
  • CDC director Rochelle Walensky said the decision "expanded the options available" to U.S. adults for vaccinations.
  • "If you have been waiting for a COVID-19 vaccine built on a different technology than those previously available, now is the time to join the millions of Americans who have been vaccinated," she said.
  • Related: Why Novavax Shares Are Plunging Today Despite Much Awaited FDA Emergency Nod?
  • The U.S. government has secured 3.2 million Novavax vaccine doses. 
  • Reuters reported that Novavax hopes its protein-based shot can reach wider acceptance among vaccine skeptics because it uses an older technology than the messenger RNA vaccines. 
  • Protein-based vaccines have been used for decades to combat hepatitis B and influenza.
  • In a 30,000-participant clinical trial, the vaccine was around 90% effective at preventing illness from COVID.
  • Price Action: NVAX shares are up 0.88% at $58.51 during the premarket session on the last check Wednesday.
  • Photo by hakan german from Pixabay
Posted In: BiotechLarge CapNewsHealth CareTop StoriesGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine